Nature Communications (May 2018)

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

  • Winson S. Ho,
  • Herui Wang,
  • Dominic Maggio,
  • John S. Kovach,
  • Qi Zhang,
  • Qi Song,
  • Francesco M. Marincola,
  • John D. Heiss,
  • Mark R. Gilbert,
  • Rongze Lu,
  • Zhengping Zhuang

DOI
https://doi.org/10.1038/s41467-018-04425-z
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 15

Abstract

Read online

Protein phosphatase 2A (PP2A) has been proposed as a target for cancer immunotherapy. Here the authors show that pharmacological inhibition of PP2A with a clinically-relevant inhibitor enhances response to immune checkpoint blockade in pre-clinical models of cancer, resulting in long lasting immunity.